Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
[PDF][PDF] Role of androgen receptor in prostate cancer: a review.
K Fujita, N Nonomura - World Journal of Men's Health, 2019 - synapse.koreamed.org
Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …
Targeting androgen receptor phase separation to overcome antiandrogen resistance
Patients with castration-resistant prostate cancer inevitably acquire resistance to
antiandrogen therapies in part because of androgen receptor (AR) mutations or splice …
antiandrogen therapies in part because of androgen receptor (AR) mutations or splice …
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
Primary resistance to androgen receptor (AR)–directed therapies in metastatic castration-
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the …
PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
PA Watson, VK Arora, CL Sawyers - Nature Reviews Cancer, 2015 - nature.com
During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-
binding domain, which is the target of enzalutamide and abiraterone, but remains …
binding domain, which is the target of enzalutamide and abiraterone, but remains …
Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
Importance A critical decision in the management of metastatic castration-resistant prostate
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a …
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a …
Targeting the p300/CBP axis in lethal prostate cancer
J Welti, A Sharp, N Brooks, W Yuan, C McNair… - Cancer …, 2021 - aacrjournals.org
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …